2007
Limitations of Green Fluorescent Protein as a Cell Lineage Marker
Swenson ES, Price JG, Brazelton T, Krause DS. Limitations of Green Fluorescent Protein as a Cell Lineage Marker. Stem Cells 2007, 25: 2593-2600. PMID: 17615263, DOI: 10.1634/stemcells.2007-0241.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlood CellsCattleCell LineageChickensCytomegalovirusFemaleFluorescent Antibody TechniqueGene ExpressionGenes, ReporterGenes, SyntheticGreen Fluorescent ProteinsHumansImmunoenzyme TechniquesMaleMiceMice, Inbred C57BLOrgan SpecificityRegulatory Sequences, Nucleic AcidTissue DistributionTransgenesVisceraConceptsSmall intestineMouse strainsPeripheral blood cellsTransgenic mouse strainReporter mouse strainPrimary rabbit antibodiesDonor originHuman ubiquitin C promoterImmunohistochemical stainingSolid organsCell lineage markersCell lineagesUBC-GFP miceUbiquitin C promoterChicken beta-actinFlow cytometryBlood cellsEnhanced green fluorescent protein (EGFP) reporterMiceOne-tissueAdult liverTissue sectionsIntestineLineage markersRabbit antibodies
2000
Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial
Yanovich S, Mitsky P, Cornetta K, Maziarz R, Rosenfeld C, Krause D, Lotz J, Bitran J, Williams S, Preti R, Somlo G, Burtness B, Mills B. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplantation 2000, 25: 1165-1174. PMID: 10849529, DOI: 10.1038/sj.bmt.1702415.Peer-Reviewed Original ResearchConceptsHigh-risk breast cancer patientsBreast cancer patientsMedian timeCancer patientsIsolated CD34Clinical trialsCell selection systemHematopoietic reconstitutionHigh-risk breast cancerCapacity of CD34Transplantation of CD34Absolute neutrophil countDuration of hospitalizationHigh-dose chemotherapyMulticenter clinical trialBone Marrow Transplantation (2000) 25Incidence of infectionPeripheral blood cellsInter-group differencesProgenitor cell graftsPlatelet engraftmentNeutrophil countCell transplantPlatelet transfusionsPlatelet count
1998
High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study
Chabannon C, Cornetta K, Lotz J, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau J, Sledge G, Novakovitch G, Srour E, Burtness B, Camerlo J, Gravis G, Lee-Fischer J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise D, Viens P. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. British Journal Of Cancer 1998, 78: 913-921. PMID: 9764583, PMCID: PMC2063121, DOI: 10.1038/bjc.1998.601.Peer-Reviewed Original ResearchConceptsPoor prognosis breast cancerHigh-dose chemotherapyHaematopoietic recoveryBreast cancerRecombinant human granulocyte colony-stimulating factorBlood cellsRandomized multicentre studyGranulocyte colony-stimulating factorHuman granulocyte colony-stimulating factorPeripheral blood cellsPeripheral blood CD34Peripheral blood progenitorsColony-stimulating factorMobilized blood cellsEpithelial tumor cellsEligible patientsStudy armsMulticentre studyPeripheral bloodConventional chemotherapyStudy groupPatientsChemotherapyBlood CD34CD34